Table of Contents  by unknown
Illustration by
Pam Curry
Volume 5, Number 2  December 2012
Table of ContentsPerspectives
45 No Residual Disease: The New Deﬁnition for Optimal Cytoreduction in Ovarian Cancer?
Monjri M. Shah, Jacob M. Estes, Ronald D. Alvarez
48 Is There a Role for Bevacizumab in the Primary Treatment of Advanced Ovarian Cancer Off-Protocol?
Jane L. Meisel, Paul Sabbatini
51 Should Dose-dense Paclitaxel in Combination With Carboplatin Be the New Standard for Treatment
for Suboptimally Debulked Patients or Patients Treated With Neoadjuvant Chemotherapy?
Marilyn Huang, Robert L. Coleman
Original Studies
53 A Phase II Study of Patupilone (EPO906) in Patients With Platinum-Resistant or Platinum-Refractory
Ovarian Cancer
Willem M. Smit, Jozef Sufliarsky, Theresa L. Werner, Don S. Dizon, Maria Wagnerová, Holger W. Hirte,
Nick M. Spirtos, Amit Oza, Luc Dirix, Mona El-Hashimy, Suddhasatta Acharyya, Eugene Y. Tan, Dirk Weber,
Jan H.M. Schellens
Effective treatment options for patients with ovarian cancer whose disease relapses or progresses within 6
months of initial therapy are limited. In the current open-label phase II study, 112 patients whose disease
relapsed during or within 6 months after completion of platinum-based therapy received the novel microtubule-
targeting agent patupilone. Patupilone was well tolerated and demonstrated promising efficacy in this difficult-
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60 Improved 8-Year Survival for Patients With Stage IIIC Ovarian Cancer Operated on at Teaching
Hospitals: Population-Based Study in Norway 2002
Torbjørn Paulsen, Witold Szczesny, Janne Kærn, Ingvild Vistad, Claes Tropé
This study aimed to determine how hospital level influenced long-term survival for patients with advanced
ovarian cancer. The study population was registered in a prospective population-based registry. All 198 women
in Norway with ovarian cancer International Federation of Gynecology and Obstetrics (FIGO) stage IIIC with
primary diagnosis during 2002 were included. Patients operated on at teaching hospitals (THs) achieved better
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retrospective study, using Surveillance, Epidemiology, and End Results (SEER)-Medicare data, we investigated
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A study of 69 paraffin-embedded ovarian tumor blocks revealed that CD3 infiltrating T cells positively correlated
with survival, melanoma-associated antigen A antigen expression correlated with poor outcome, and high
numbers of FoxP3 cells with advanced disease. Identification of parameters associated with survival will
contribute toward the development of tests for early diagnosis and to the design of modern therapies in ovarian
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Access to secondary specialist services is important for women with suspected uterine cancer. Shorter waiting
times lead to earlier diagnosis and improved outcomes. This study compared waiting times for 147 women
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